Friday, August 8, 2025
StockstToday.com Logo
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Sotagliflozin Shows Promise in Improving Glycemic Control for Patients with Type 1 Diabetes and Chronic Kidney Disease

Elaine Mendonca by Elaine Mendonca
March 12, 2024
in Breaking News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Lexicon Pharmaceuticals, Inc. revealed groundbreaking findings from a recent post hoc analysis of the inTandem3 study on March 12, 2024. The analysis showcased significant advancements in glycemic control among patients with type 1 diabetes and chronic kidney disease who received sotagliflozin treatment.

________________________________

The data revealed that sotagliflozin effectively decreased A1C levels, body weight, and systolic blood pressure, all while maintaining a safety profile comparable to the overall study group. These results were presented at the ATTD 2024 conference in Florence, Italy, shedding light on the positive impact of sotagliflozin on key parameters in patients with type 1 diabetes and CKD.

________________________________

Interestingly, the analysis demonstrated consistent effects of sotagliflozin on A1C, body weight, and systolic blood pressure in both the CKD subgroup and the total cohort. Moreover, the risks of severe hypoglycemia were found to be similar between the two groups.

________________________________

Dr. David Z.I. Cherney, a respected Professor at the University of Toronto and a key author of the abstract presented at ATTD, emphasized the uniform benefits of sotagliflozin across different patient subgroups with type 1 diabetes and CKD. These findings underscore the potential of sotagliflozin as a promising new treatment option for this specific patient population.

Lexicon Pharmaceuticals Inc. (LXRX) Shows Strong Price Momentum with Impressive Gains – March 12, 2024

On March 12, 2024, Lexicon Pharmaceuticals Inc. (LXRX) showed strong price momentum as it traded in the middle of its 52-week range and above its 200-day simple moving average. The stock had experienced a significant increase in price, with shares rising by $0.64 since the market last closed, representing a 29.49% increase. The stock had closed at $2.81.

However, in pre-market trading, LXRX saw a slight drop of $0.06. This drop in pre-market trading may indicate some profit-taking by investors or a shift in market sentiment. Despite this drop, the stock had still shown impressive gains over the previous trading session.

Lexicon Pharmaceuticals, Inc. Sees Significant Revenue Growth in 2024: A Financial Analysis

On March 12, 2024, Lexicon Pharmaceuticals, Inc. (LXRX) saw a significant increase in its total revenue compared to the previous year and quarter. The company reported total revenue of $1.20 million for the past year, representing a 766.19% increase from the previous year, and $702.00 thousand for the last quarter, a 333.33% increase from the previous quarter.

Despite the positive revenue growth, Lexicon Pharmaceuticals, Inc. also reported a net income loss for both the past year and quarter. The company’s net income was -$175.61 million for the past year, a 72.26% decrease from the previous year, and -$48.24 million for the last quarter, showing no change from the previous quarter.

In terms of earnings per share (EPS), Lexicon Pharmaceuticals, Inc. reported a decrease in EPS compared to the previous year but an increase from the previous quarter. The company’s EPS was -$0.79 for the past year, a 29.1% decrease from the previous year, and -$0.20 for the last quarter, a 4.51% increase from the previous quarter.

Overall, the stock performances of LXRX on March 12, 2024, reflected a mixed financial picture for the company. Investors may want to closely monitor Lexicon Pharmaceuticals, Inc.’s financial performance and future growth prospects to make informed investment decisions.

Tags: LXRX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Core Molding Technologies AMEXCMT Reports Strong Earnings Growth but Decline in Sales

Automotive Stock Market Today

Volvo Partners with SaverOne to Enhance Bus Safety in Mexico

IT-Healthcare

Inspira Technologies VORTX Device A Groundbreaking Advancement in Blood Oxygenation Technology

Recommended

ALB stock news

Allspring Global Investments Increases Stake in Automotive Parts Company, Douglas Dynamics Inc.

2 years ago
Technology Robotics Markets and money

Exela Technologies Inc and XBP Europe Launch Reaktrai Revolutionizing Cybersecurity and Data Management with AI

2 years ago

Positive Outlook and Increased Price Target for Corteva

2 years ago
Alternative Energy Markets and money (1)

Ecopetrols Commitment to Thorough Evaluation and Reliable Results for Arauca 8 Well

2 years ago

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

Topics

AAL AAPL ABNB ADBE ADSK ALB AMD AMZN AVGO BA C CCL CELH COIN COST CRWD CTVA DELL DFS DIS DLR DLTR DWAC GM GRFS IBM INTC JPM KSS LLY META MSFT NFLX NVDA NVO ORCL PARA PLTR PLUG QCOM SMCI TGT TSLA UNH VZ
No Result
View All Result

Highlights

Lucid Group Stock: Turbulence Amid Policy Shifts and Uber Deal

Walt Disney Stock: Marvel Woes Offset by NFL Deal

Fresenius Stock: Mixed Q2 Results Amid Margin Pressures

Beiersdorf Stock: Nivea’s Glow Fades as Forecasts Dim

ABN Amro Stock: Profit Dip Amid Strong Capital Moves

Vonovia Stock: Strong Recovery Fuels Optimism

Trending

Snap Stock
Stocks

Snap Stock: Turmoil Amid Advertising Woes

by Dieter Jaworski
August 6, 2025
0

Snap Inc.'s stock has become a battleground for Wall Street analysts following disappointing Q2 results, with price...

DHL Stock

DHL Stock: Rollercoaster Ride Amid Strong Earnings

August 6, 2025
Klöckner Stock

Klöckner Stock: Turnaround Amid Market Volatility

August 6, 2025
Lucid Group Stock

Lucid Group Stock: Turbulence Amid Policy Shifts and Uber Deal

August 6, 2025
Walt Disney Stock

Walt Disney Stock: Marvel Woes Offset by NFL Deal

August 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • Gilead Sciences Stock: HIV Breakthrough Fuels Rally August 8, 2025
  • Apple Stock: Surges on Tariff Exemption and $600B US Pledge August 8, 2025
  • Yandex Stock: Cloud Specialist Nebius Soars on Record Growth August 7, 2025

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings

© 2023 StocksToday.com